Fibroblast activation protein (FAP) is abundantly expressed in the stroma of most human solid tumors. Clinical-stage radiolabeled FAP ligands are increasingly used as tools for the detection of various cancer lesions. To unleash the full therapeutic potential of FAP-targeting agents, ligands need to remain at the tumor site for several days after administration. We recently described the discovery of OncoFAP, a high-affinity small organic ligand of FAP with a rapid accumulation in tumors and low uptake in healthy tissues in cancer patients. Trimerization of OncoFAP provided a derivative (named TriOncoFAP, or OncoFAP-23) with improved FAP affinity. In this work, we evaluated the tissue biodistribution profile and the therapeutic performance of OncoFAP-23 in tumor-bearing mice. Methods: OncoFAP-23 was radiolabeled with the theranostic radionuclide ¹⁷⁷Lu. Preclinical experiments were conducted on mice bearing SK-RC-52.hFAP (BALB/c nude mice) or CT-26.hFAP (BALB/c mice) tumors. ¹⁷⁷Lu-OncoFAP and ¹⁷⁷Lu-FAP-2286 were included in the biodistribution study as controls. Toxicologic evaluation was performed on Wistar rats and CD1 mice by injecting high doses of OncoFAP-23 or its cold-labeled counterpart, respectively. Results: ¹⁷⁷Lu-OncoFAP-23 emerged for its best-in-class biodistribution profile, high and prolonged tumor uptake (i.e., ~16 percentage injected dose/g at 96 h), and low accumulation in healthy organs, which correlates well with its potent single-agent anticancer activity at low levels of administered radioactivity. Combination treatment with the tumor-targeted interleukin 2 (L19-IL2, a clinical-stage immunocytokine) further expands the therapeutic window of ¹⁷⁷Lu-OncoFAP-23 by potentiating its in vivo antitumor activity. Proteomics studies revealed a potent tumor-directed immune response on treatment with the combination. OncoFAP-23 and ^natLu-OncoFAP-23 exhibited a favorable toxicologic profile, without showing any side effects or signs of toxicity. Conclusion: OncoFAP-23 presents enhanced tumor uptake and tumor retention and low accumulation in healthy organs, findings that correspond to a strongly improved in vivo antitumor efficacy. The data presented in this work support the clinical development of ¹⁷⁷Lu-OncoFAP-23 for the treatment of FAP-positive solid tumors.

Around 3% of people are thought to hear voices when there is no one talking.

Archaeologists in Saqqara make a dazzling discovery: a late period Egyptian coffin with a gilded mask. Now, to bring it to the surface, they use a pulley known as a "tambora," a technology that dates back to Ancient Egypt

Coffee - it's a staple of American life, and inside the vaults of the National Museum of American History, they know the secret to its wide spread success: packaging

The first coffin Marcus Daly built was for his own child. Now, he has mastered the art of creating a final resting place for so many

Honeybees get a caffeine buzz and memory boost when they drink coffee nectar

Merry "Corky" White, author of Coffee Life in Japan, traces the history of coffee culture in the United States

New research suggests the sarcophagus' occupant, previously known only as "the horseman," is Joachim du Bellay, a French Renaissance poet who died in 1560

The 4,000-year-old burial chamber featured hieroglyphs referring to the woman, known as Idi, as the "lady of the house"

500 children attended the children’s program and hundreds of visitors came to the Bus4Life in Moldova. The team was amazed at the response.

MAP Australia hosts Bound for Paradise, a week-long outreach to Muslims from the Persian Gulf in Queensland, Australia, from 25-29 August.

In August 2024, Pennsylvania resident Max Justice launched Setas Eternal Living. His flagship product, MyCoffin, is a biodegradable coffin made from mycelium, the root structure of mushrooms. Justice has utilized resources provided by Penn State Law's Entrepreneur Assistance and Intellectual Property clinics and Happy Valley LaunchBox to grow his business. 

Jose, an Argentinian worker serving in Southeast Asia, tells of how he entered overseas service and what he has seen God do through his not-so-typical ministry.

Street evangelism - that’s how Nicolas ended up carrying a 2 meter high cardboard coffin on a bus across Santiago, Chile.

The action is viewed as a modest but significant attempt to raise staff morale in the wake of recent budget cuts.

IN a country with a rich tea-drinking tradition spanning thousands of years, China saw its first cohort of university students majoring in coffee science and engineering start the new semester this month. This

The latest research on caffeine reveals why coffee and decaf can be so good for your health, but energy drinks can be lethal

Title: You Can Drink Coffee With Your Thyroid Medication: Study
Category: Health News
Created: 6/13/2022 12:00:00 AM
Last Editorial Review: 6/13/2022 12:00:00 AM

Title: Could Heavy Coffee Drinking Help Men Battle Prostate Cancer?
Category: Health News
Created: 8/26/2013 7:36:00 PM
Last Editorial Review: 8/27/2013 12:00:00 AM

Title: Coffee Cravings May Spring From Your DNA
Category: Health News
Created: 8/25/2016 12:00:00 AM
Last Editorial Review: 8/25/2016 12:00:00 AM

Title: Drink Coffee, Live Longer?
Category: Health News
Created: 8/28/2017 12:00:00 AM
Last Editorial Review: 8/29/2017 12:00:00 AM

Title: Why Coffee & Cigarette Is a Morning Ritual for Millions
Category: Health News
Created: 8/22/2022 12:00:00 AM
Last Editorial Review: 8/22/2022 12:00:00 AM

Title: Does Hot Chocolate Have Caffeine? Hot Chocolate vs. Coffee & Tea
Category: Health and Living
Created: 8/26/2022 12:00:00 AM
Last Editorial Review: 8/26/2022 12:00:00 AM

Title: Does Coffee Raise Cholesterol?
Category: Health News
Created: 5/11/2022 12:00:00 AM
Last Editorial Review: 5/12/2022 12:00:00 AM

The latest research on caffeine reveals why coffee and decaf can be so good for your health, but energy drinks can be lethal

Later this month on September 27th, NIS America will release FuRyu’s action RPG Reynatis for Switch, Steam, PS5, and PS4 …

Continue reading "Reynatis Interview: Creative Producer TAKUMI, Scenario Writer Kazushige Nojima, and Composer Yoko Shimomura discuss the game, coffee, and more"

When I first wrote about boomer shooters last year on Steam Deck and also on Switch, aside from New Blood …

Continue reading "Andrew Hulshult 2024 Interview: DOOM IDKFA, Blood Swamps, DUSK, Iron Lung, AMID EVIL, Music, Guitars, Cold Brew Coffee, and More"

Apple has a history of eye-popping price tags, but the company is reaching new heights with a product that isn't even a gadget. After Apple Music unveiled a list of the 100 best albums of all time earlier this year, the streaming service is releasing a companion coffee table book. You can grab one of the 1,500 copies for a cool $450.

I find these endeavors to rank and quantify art hilarious, because music is subjective and personal by nature. But people do love to debate their own artistic opinions, so if that's your jam there's plenty to dig into with Apple Music's assessment. (And before you ask, the top spot was claimed by The Miseducation of Lauryn Hill.) This particular countdown was assembled by "Apple Music’s team of experts alongside an exclusive group of artists including Maren Morris, Pharrell Williams, J Balvin, Charli XCX, Mark Hoppus, Honey Dijon and Nia Archives, as well as songwriters, producers and industry professionals," according to the book listing.

I'm sure this limited-run hardcover will be very beautiful, and maybe the liner notes analyzing each entry are deeply insightful. But I also wonder who would bother to buy it. If you are one of those 1,500 people who wants one, the book is due to start shipping in January.

This article originally appeared on Engadget at https://www.engadget.com/entertainment/music/the-coffee-table-book-of-apple-musics-best-100-albums-will-set-you-back-450-193018825.html?src=rss

IF you buy a large cappuccino you may find it is quite cold by the time you get to the bottom. Thankfully, there is now a solution to this.

Results reporting requirements are pretty clear. Maybe critics should re-check their methods?

Ben Goldacre has rather famously described the clinical trial reporting requirements in the Food and Drug Administration Amendments Act of 2007 as a “fake fix” that was being thoroughly “ignored” by the pharmaceutical industry.

Pharma: breaking the law in broad daylight?

He makes this sweeping, unconditional proclamation about the industry and its regulators on the basis of  a single study in the BMJ, blithely ignoring the fact that a) the authors of the study admitted that they could not adequately determine the number of studies that were meeting FDAAA requirements and b) a subsequent FDA review that identified only 15 trials potentially out of compliance, out of a pool of thousands.


Despite the fact that the FDA, which has access to more data, says that only a tiny fraction of studies are potentially noncompliant, Goldacre's frequently repeated claims that the law is being ignored seems to have caught on in the general run of journalistic and academic discussions about FDAAA.

And now there appears to be additional support for the idea that a large percentage of studies are noncompliant with FDAAA results reporting requirements, in the form of a new study in the Journal of Clinical Oncology: "Public Availability of Results of Trials Assessing Cancer Drugs in the United States" by Thi-Anh-Hoa Nguyen, et al.. In it, the authors report even lower levels of FDAAA compliance – a mere 20% of randomized clinical trials met requirements of posting results on clinicaltrials.gov within one year.

Unsurprisingly, the JCO results were immediately picked up and circulated uncritically by the usual suspects.

I have to admit not knowing much about pure academic and cooperative group trial operations, but I do know a lot about industry-run trials – simply put, I find the data as presented in the JCO study impossible to believe. Everyone I work with in pharma trials is painfully aware of the regulatory environment they work in. FDAAA compliance is a given, a no-brainer: large internal legal and compliance teams are everywhere, ensuring that the letter of the law is followed in clinical trial conduct. If anything, pharma sponsors are twitchily over-compliant with these kinds of regulations (for example, most still adhere to 100% verification of source documentation – sending monitors to physically examine every single record of every single enrolled patient - even after the FDA explicitly told them they didn't have to).

I realize that’s anecdotal evidence, but when such behavior is so pervasive, it’s difficult to buy into data that says it’s not happening at all. The idea that all pharmaceutical companies are ignoring a highly visible law that’s been on the books for 6 years is extraordinary. Are they really so brazenly breaking the rules? And is FDA abetting them by disseminating incorrect information?

Those are extraordinary claims, and would seem to require extraordinary evidence. The BMJ study had clear limitations that make its implications entirely unclear. Is the JCO article any better?

Some Issues

In fact, there appear to be at least two major issues that may have seriously compromised the JCO findings:

1. Studies that were certified as being eligible for delayed reporting requirements, but do not have their certification date listed.

The study authors make what I believe to be a completely unwarranted assumption:

In trials for approval of new drugs or approval for a new indication, a certification [permitting delayed results reporting] should be posted within 1 year and should be publicly available.

It’s unclear to me why the authors think the certifications “should be” publicly available. In re-reading FDAAA section 801, I don’t see any reference to that being a requirement. I suppose I could have missed it, but the authors provide a citation to a page that clearly does not list any such requirement.

But their methodology assumes that all trials that have a certification will have it posted:

If no results were posted at ClinicalTrials.gov, we determined whether the responsible party submitted a certification. In this case, we recorded the date of submission of the certification to ClinicalTrials.gov.

If a sponsor gets approval from FDA to delay reporting (as is routine for all drugs that are either not approved for any indication, or being studied for a new indication – i.e., the overwhelming majority of pharma drug trials), but doesn't post that approval on the registry, the JCO authors deem that trial “noncompliant”. This is not warranted: the company may have simply chosen not to post the certification despite being entirely FDAAA compliant.

2. Studies that were previously certified for delayed reporting and subsequently reported results

It is hard to tell how the authors treated this rather-substantial category of trials. If a trial was certified for delayed results reporting, but then subsequently published results, the certification date becomes difficult to find. Indeed, it appears in the case where there were results, the authors simply looked at the time from study completion to results posting. In effect, this would re-classify almost every single one of these trials from compliant to non-compliant. Consider this example trial:

• Phase 3 trial completes January 2010
• Certification of delayed results obtained December 2010 (compliant)
• FDA approval June 2013
• Results posted July 2013 (compliant)

In looking at the JCO paper's methods section, it really appears that this trial would be classified as reporting results 3.5 years after completion, and therefore be considered noncompliant with FDAAA. In fact, this trial is entirely kosher, and would be extremely typical for many phase 2 and 3 trials in industry.

Time for Some Data Transparency

The above two concerns may, in fact, be non-issues. They certainly appear to be implied in the JCO paper, but the wording isn't terribly detailed and could easily be giving me the wrong impression.

However, if either or both of these issues are real, they may affect the vast majority of "noncompliant" trials in this study. Given the fact that most clinical trials are either looking at new drugs, or looking at new indications for new drugs, these two issues may entirely explain the gap between the JCO study and the unequivocal FDA statements that contradict it.

I hope that, given the importance of transparency in research, the authors will be willing to post their data set publicly so that others can review their assumptions and independently verify their conclusions. It would be more than a bit ironic otherwise.
Thi-Anh-Hoa Nguyen, Agnes Dechartres, Soraya Belgherbi, and Philippe Ravaud (2013). Public Availability of Results of Trials Assessing Cancer Drugs in the United States JOURNAL OF CLINICAL ONCOLOGY DOI: 10.1200/JCO.2012.46.9577

New Craft Coffee Products from KitchenAid

With a Keurig� in every room at Holiday Inn Express� hotels, smart travelers � like actor/comedian Rob Riggle � can get a great cup of coffee with just the push of a button.

Bielke & Yang made a packaging redesign for Talor&Jørgen coffee...

The post Coffee packaging for Talor&Jørgen first appeared on peopleofdesign.

Start-ups launch drinks that look and taste like coffee but they say are better for the environment.

New role will oversee research-for-development capabilities across Africa.

The post IWMI appoints Olufunke Cofie as Africa Director for Research Impact first appeared on International Water Management Institute (IWMI).

It can be seen as part of human nature that over a period of time, people become bored with routine activities, such as eating, drinking and repetitive...

In the range of commercial coffee machines, Espresso is a name which is worth to rely. This Italian flavor rules the heart of the coffee lovers’ right from its origin. Considering its charm throughout the world, Espresso comes...

When it comes to coffee beans, what happens in Brazil doesn’t stay in Brazil. In July and August, a bad frost hit the country's coffee-producing region and analysts say Brazil’s bean shortage is already rattling the global coffee market. So how will the frost affect the price of your morning cup? WSJ’s Shelby Holliday spoke to coffee experts around the world to find out. Illustration: Rafael Garcia

Starbucks trails only McDonald’s as the largest restaurant chain by market capitalization. WSJ’s Heather Haddon explains why mobile technology has become a business priority for Starbucks and garnered it a loyal customer base. Photo: Stanislav Kogiku/Zuma Press

A coffee table makes an essential furniture piece that binds up the seating zone or is predominantly your living room. It is of course a functional piece that makes an ideal surface to place your coffee mug, newspapers, TV remote, and

A coffee table is one of the most essential and functional pieces of furniture you think of investing in when setting up a home. Your seating arrangement will practically remain incomplete if you don't place a coffee table in front of

Can a coffee cup determine your success at an interview? Well, we've all been there; nervously sitting in a job interview, knowing that our future hangs in the balance. Some interviews are tough, while others might feel surprisingly straightforward. Here an

The beverage of choice at cafes mushrooming in metros and small towns alike is proving a strong draw for VC investments too

Kaapi 2.0, a new chain of minimalist cafes in the city, offers healthy snack options to munch on along with filter coffee

This situation occurs when the aircraft’s low-speed stall and high-speed buffet meet

Araku Coffee co-founder and CEO Manoj Kumar on the journey of the award-winning brand